Diurnal Group (DNL) Share Price, News & Analysis

Company Overview

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 27.30 to 27.30
• 52-Week Range: N/A
• Volume: 145,283 shs
• Average Volume: 483,617 shs
• Market Capitalization: £46.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DNL Stock Analysis - Frequently Asked Questions

How were Diurnal Group's earnings last quarter?

Diurnal Group plc (LON:DNL) posted its earnings results on Tuesday, September, 15th. The company reported ($4.30) earnings per share for the quarter, beating the consensus estimate of ($6.70) by $2.40.

How do I buy shares of Diurnal Group?

Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Diurnal Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diurnal Group investors own include Allena Pharmaceuticals (ALNA), Active Energy Group (AEG), C3.ai (AI), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), B&M European Value Retail (BME) and Cerecor (CERC).

Company Calendar

• Last Earnings: 9/15/2020
• Today: 7/16/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:DNL
• CIK: N/A
• Web: www.diurnal.co.uk
• Phone: +44-29-20682069
• Fax: N/A
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.77
• Current Ratio: 5.23
• Quick Ratio: 4.16

Sales & Book Value

• Annual Sales: £4.68 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 2.81
• Book Value: GBX 12.70 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 169,720,000
• Free Float: N/A
• Market Cap: £46.33 million
• Optionable: Not Optionable
• Beta: N/A